1. Home
  2. ALVR

as 05-30-2024 1:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.

Founded: 2013 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 87.1M IPO Year: 2020
Target Price: $5.88 AVG Volume (30 days): 438.4K
Analyst Decision: Hold Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.66 EPS Growth: N/A
52 Week Low/High: $0.58 - $6.12 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of AlloVir Inc. (ALVR)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Sinha Vikas ALVR See Remarks May 17 '24 Sell $0.75 3,143 $2,355.05 1,129,996 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer May 17 '24 Sell $0.75 541 $405.37 75,481 SEC Form 4
Brainard Diana ALVR Chief Executive Officer May 3 '24 Sell $0.80 10,240 $8,151.04 792,695 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer May 3 '24 Sell $0.80 1,597 $1,271.21 76,022 SEC Form 4
Sinha Vikas ALVR See Remarks May 3 '24 Sell $0.80 4,957 $3,945.77 1,133,139 SEC Form 4
Brainard Diana ALVR Chief Executive Officer Apr 19 '24 Sell $0.75 9,601 $7,206.51 802,935 SEC Form 4
Sinha Vikas ALVR See Remarks Apr 19 '24 Sell $0.75 1,521 $1,141.66 1,139,953 SEC Form 4
Sinha Vikas ALVR See Remarks Apr 19 '24 Sell $0.75 1,857 $1,392.75 1,138,096 SEC Form 4
Miller Edward ALVR General Counsel Apr 2 '24 Sell $0.77 368 $284.10 224,610 SEC Form 4
Sinha Vikas ALVR See Remarks Apr 2 '24 Sell $0.77 885 $683.22 1,141,474 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer Feb 20 '24 Sell $0.70 494 $343.43 78,853 SEC Form 4
Brainard Diana ALVR Chief Executive Officer Feb 20 '24 Sell $0.70 3,097 $2,153.03 819,224 SEC Form 4
Brainard Diana ALVR Chief Executive Officer Feb 20 '24 Sell $0.71 5,155 $3,650.26 814,069 SEC Form 4
Miller Edward ALVR General Counsel Feb 20 '24 Sell $0.70 385 $267.65 224,978 SEC Form 4
Sinha Vikas ALVR See Remarks Feb 20 '24 Sell $0.70 2,893 $2,011.21 1,142,359 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer Feb 8 '24 Sell $0.67 11,150 $7,493.92 79,347 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer Feb 5 '24 Sell $0.67 5,792 $3,880.64 90,497 SEC Form 4
Miller Edward ALVR General Counsel Feb 5 '24 Sell $0.67 8,869 $5,942.23 225,363 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer Jan 23 '24 Sell $0.67 901 $604.39 96,289 SEC Form 4
Sinha Vikas ALVR See Remarks Jan 23 '24 Sell $0.67 3,205 $2,149.91 1,163,583 SEC Form 4
Miller Edward ALVR General Counsel Jan 23 '24 Sell $0.67 1,302 $873.38 234,232 SEC Form 4
Hagen Brett R ALVR Chief Accounting Officer Jan 4 '24 Sell $0.64 310 $198.09 97,190 SEC Form 4
Miller Edward ALVR General Counsel Jan 4 '24 Sell $0.64 424 $270.94 235,534 SEC Form 4
Sinha Vikas ALVR See Remarks Jan 4 '24 Sell $0.64 961 $614.08 1,166,788 SEC Form 4
Brainard Diana ALVR Chief Executive Officer Jan 4 '24 Sell $0.64 1,664 $1,063.30 873,242 SEC Form 4

Share on Social Networks: